In a nutshell This phase 2 trial will investigate the effects of tesetaxel combined with targeted therapy drugs in advanced breast cancer (BC). The main outcomes will be the overall response rate (ORR) and progression-free survival (PFS). This trial is recruiting in Boston, MA and East Setauket, NY. The details Some...
Read More
In a nutshell This trial is examining the effectiveness of crenolanib after salvage chemotherapy for relapsed or unresponsive acute myeloid leukemia (AML) with FLT3 activating mutations. The main outcome would be survival without complications from leukemia 3 years after the treatment has finished. The details AML is a type of blood...
Read More
In a nutshell This study is evaluating how well a new chemoimmunotherapy regimen works in treating patients with classical Hodgkin’s lymphoma (cHL) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer after treatment. This study...
Read More
In a nutshell This phase 1 trial will investigate the safety of an experimental drug, XmAb22841 (XmAb), to treat advanced cancer. The main outcome will be the safety and tolerability of XmAb. This study is recruiting in Georgia and Texas, USA. The details Advanced cancer can be difficult to treat. New drugs are being developed to address this. Immune...
Read MoreIn a nutshell This phase 1/2 trial will investigate the safety of 9-ING-41, for treatment-resistant cancers. The main outcome will be the number of treatment-related adverse events (TRAEs). This trial is recruiting in the United States. The details Some cancers may not respond to conventional treatment. Treatment-resistant cancers are called...
Read MoreIn a nutshell This phase 2 trial will investigate the effectiveness of stereotactic body radiotherapy (SBRT) in patients with metastatic cancer. The main outcome will be progression-free survival (PFS; survival without the cancer getting worse). This trial is recruiting in multiple locations in New York and New Jersey, US. The details...
Read MoreIn a nutshell This study wanted to find out if treating recurrent non-small cell lung cancer with ramucirumab (Cyramza) and pembrolizumab (Keytruda) works better than standard care practices. The main outcome that will be measured is the overall survival rates. This study will take place in the United States. The details There are a...
Read MoreIn a nutshell This trial aims to find out how safe talazoparib (Talzenna) followed by a combination of talazoparib and avelumab (Bavencio) is in patients with advanced breast cancer. The main outcome that will be measured is if patients have side effects. This study is being conducted in Washington, the United States. The...
Read MoreIn a nutshell This study wants to find out how well talazoparib (Talzenna) and temozolomide (Temodal) work for treating patients with small cell lung cancer that has come back after or was unresponsive to initial chemotherapy. The main outcome that will be measured is how long the patients go before the cancer grows. The study is...
Read More
In a nutshell This phase 1 study will investigate the dose range and effectiveness of an experimental drug, XmAb23104, in the treatment of advanced lung cancer and other solid tumors. The main outcome will be the safety and tolerability of XmAb23104. This trial is recruiting in Georgia, Texas, and Virginia, the United States. The details Advanced...
Read MoreIn a nutshell This phase 2 study will investigate Tavokinogene Telseplasmid Electroporation (TTE) in combination with pembrolizumab (Keytruda) in advanced or not suitable for surgery triple-negative breast cancer (TNBC). The main outcome will be the objective response rate (ORR). This trial is recruiting in the United States and...
Read MoreIn a nutshell This phase 2 trial is examining the effectiveness and safety of navarixin (MK-7123) in combination with pembrolizumab (Keytruda) in patients with non-small cell lung cancer (NSCLC). The main outcome to be measured will be the objective response rate (ORR; tumor shrinkage or disappearance). The details A treatment option for...
Read More
